Treatment with tyrosine kinase inhibitors (TKIs) specifically targeting BCR-ABL by binding to the ATP-binding site of Abl, such as imatinib and dasatinib, results in significant improvement in clinical responses of CML patients [3, 4]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.